Sanofi (NASDAQ:SNY) Upgraded to “Hold” at Deutsche Bank Aktiengesellschaft

Sanofi (NASDAQ:SNY) was upgraded by stock analysts at Deutsche Bank Aktiengesellschaft from a “sell” rating to a “hold” rating in a report released on Thursday, Marketbeat Ratings reports.

Separately, StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $60.00.

Sanofi Price Performance

NASDAQ SNY opened at $54.34 on Thursday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The company has a market cap of $137.91 billion, a PE ratio of 27.72, a P/E/G ratio of 1.21 and a beta of 0.57. The firm’s 50 day moving average price is $49.24 and its 200-day moving average price is $52.27. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. Sell-side analysts forecast that Sanofi will post 3.82 EPS for the current fiscal year.

Institutional Trading of Sanofi

Large investors have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. lifted its stake in Sanofi by 31.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock valued at $8,040,000 after buying an additional 33,105 shares in the last quarter. Arkadios Wealth Advisors lifted its holdings in shares of Sanofi by 19.0% during the 4th quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock valued at $227,000 after acquiring an additional 751 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Sanofi by 7.1% in the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock valued at $14,681,000 after buying an additional 16,780 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Sanofi by 20.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after buying an additional 399,301 shares during the period. Finally, GFS Advisors LLC boosted its stake in shares of Sanofi by 1,017.9% during the 3rd quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock valued at $738,000 after buying an additional 11,655 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.